216 related articles for article (PubMed ID: 36508702)
1. Development of a Core Set of Patient- and Caregiver-Reported Signs and Symptoms to Facilitate Early Recognition of Acute Chimeric Antigen Receptor T-Cell Therapy Toxicities.
Spanjaart AM; Pennings ERA; Kos M; Mutsaers PGNJ; Lugtenburg PJ; van Meerten T; van Doesum JA; Minnema MC; Jak M; van Dorp S; Vermaat JSP; van der Poel MWM; van Oijen MGH; Kuipers MT; Nijhof IS; Kersten MJ
JCO Oncol Pract; 2023 Mar; 19(3):e407-e416. PubMed ID: 36508702
[TBL] [Abstract][Full Text] [Related]
2. Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.
Chakraborty R; Sidana S; Shah GL; Scordo M; Hamilton BK; Majhail NS
Biol Blood Marrow Transplant; 2019 May; 25(5):e155-e162. PubMed ID: 30500439
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cell Therapy: A Comprehensive Review of Clinical Efficacy, Toxicity, and Best Practices for Outpatient Administration.
Alexander M; Culos K; Roddy J; Shaw JR; Bachmeier C; Shigle TL; Mahmoudjafari Z
Transplant Cell Ther; 2021 Jul; 27(7):558-570. PubMed ID: 33910041
[TBL] [Abstract][Full Text] [Related]
4. Patient-Reported Symptom and Functioning Status during the First 12 Months after Chimeric Antigen Receptor T Cell Therapy for Hematologic Malignancies.
Wang XS; Srour SA; Whisenant M; Subbiah IM; Chen TH; Ponce D; Gonzalez AG; Kamal M; Mendoza T; Cleland CS; Kebriaei P; Neelapu SS; Rezvani K; Ahmed S; Shpall E
Transplant Cell Ther; 2021 Nov; 27(11):930.e1-930.e10. PubMed ID: 34265479
[TBL] [Abstract][Full Text] [Related]
5. Chimeric antigen receptor (CAR) T-cell therapy for people with relapsed or refractory diffuse large B-cell lymphoma.
Ernst M; Oeser A; Besiroglu B; Caro-Valenzuela J; Abd El Aziz M; Monsef I; Borchmann P; Estcourt LJ; Skoetz N; Goldkuhle M
Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013365. PubMed ID: 34515338
[TBL] [Abstract][Full Text] [Related]
6. Quality of life in caregivers of patients receiving chimeric antigen receptor T-cell therapy.
Barata A; Hoogland AI; Hyland KA; Otto AK; Kommalapati A; Jayani RV; Irizarry-Arroyo N; Collier A; Rodriguez Y; Welniak TL; Booth-Jones M; Logue J; Small BJ; Jain MD; Reblin M; Locke FL; Jim HSL
Psychooncology; 2021 Aug; 30(8):1294-1301. PubMed ID: 33739548
[TBL] [Abstract][Full Text] [Related]
7. Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
Oluwole OO; Dholaria B; Knight TE; Jain T; Locke FL; Ramsdell L; Nikiforow S; Hashmi H; Mooney K; Bhaskar ST; Morris K; Gatwood K; Baer B; Anderson LD; Hamadani M
Transplant Cell Ther; 2024 Feb; 30(2):131-142. PubMed ID: 37951502
[TBL] [Abstract][Full Text] [Related]
8. Next-Generation Implementation of Chimeric Antigen Receptor T-Cell Therapy Using Digital Health.
Banerjee R; Shah N; Dicker AP
JCO Clin Cancer Inform; 2021 Jun; 5():668-678. PubMed ID: 34110929
[TBL] [Abstract][Full Text] [Related]
9. Quality Assessment of Pre-Clinical Studies of Chimeric Antigen Receptor T-Cell Therapy Products: A Point of Focus on Safety.
Maharshi V; Diksha D; Gupta P
Curr Drug Saf; 2022; 17(2):129-135. PubMed ID: 34323195
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of CD22 chimeric antigen receptor (CAR) T cell therapy in patients with B cell malignancies: a protocol for a systematic review and meta-analysis.
Adeel K; Fergusson NJ; Shorr R; Atkins H; Hay KA
Syst Rev; 2021 Jan; 10(1):35. PubMed ID: 33478595
[TBL] [Abstract][Full Text] [Related]
11. Clinical Presentation, Risk Factors, and Outcomes of Immune Effector Cell-Associated Neurotoxicity Syndrome Following Chimeric Antigen Receptor T Cell Therapy: A Systematic Review.
Grant SJ; Grimshaw AA; Silberstein J; Murdaugh D; Wildes TM; Rosko AE; Giri S
Transplant Cell Ther; 2022 Jun; 28(6):294-302. PubMed ID: 35288347
[TBL] [Abstract][Full Text] [Related]
12. A review of chimeric antigen receptor T-cells in lymphoma.
Anderson JK; Mehta A
Expert Rev Hematol; 2019 Jul; 12(7):551-561. PubMed ID: 31177852
[No Abstract] [Full Text] [Related]
13. 2022 Chinese expert consensus and guidelines on clinical management of toxicity in anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Li P; Liu Y; Liang Y; Bo J; Gao S; Hu Y; Hu Y; Huang H; Huang X; Jing H; Ke X; Li J; Li Y; Liu Q; Lu P; Mei H; Niu T; Song Y; Song Y; Su L; Tu S; Wang J; Wu D; Wang Z; Xu K; Ying Z; Yang Q; Zhang Y; Shi F; Zhang B; Zhang H; Zhang X; Zhao M; Zhao W; Zhao X; Huang L; Zhu J; Qian W; Han W; Liang A
Cancer Biol Med; 2023 Mar; 20(2):129-46. PubMed ID: 36861439
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
15. Tocilizumab for the treatment of chimeric antigen receptor T cell-induced cytokine release syndrome.
Kotch C; Barrett D; Teachey DT
Expert Rev Clin Immunol; 2019 Aug; 15(8):813-822. PubMed ID: 31219357
[No Abstract] [Full Text] [Related]
16. Chimeric Antigen Receptor T-Cell Therapy for the Community Oncologist.
Maus MV; Levine BL
Oncologist; 2016 May; 21(5):608-17. PubMed ID: 27009942
[TBL] [Abstract][Full Text] [Related]
17. Chimeric Antigen Receptor T Cell Therapy for Pediatric B-ALL: Narrowing the Gap Between Early and Long-Term Outcomes.
Schultz L
Front Immunol; 2020; 11():1985. PubMed ID: 32849662
[TBL] [Abstract][Full Text] [Related]
18. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
Strati P; Neelapu SS
Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
[TBL] [Abstract][Full Text] [Related]
19. CAR-T Cell Therapy: the Efficacy and Toxicity Balance.
Chohan KL; Siegler EL; Kenderian SS
Curr Hematol Malig Rep; 2023 Apr; 18(2):9-18. PubMed ID: 36763238
[TBL] [Abstract][Full Text] [Related]
20. Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions.
Wat J; Barmettler S
J Allergy Clin Immunol Pract; 2022 Feb; 10(2):460-466. PubMed ID: 34757064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
